The global renal failure treatment market size is calculated at USD 132.28 billion in 2025 and is forecasted to reach around USD 273.38 billion by 2034, accelerating at a CAGR of 8.40% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Renal Failure Treatment Market Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Renal Failure Treatment Market, by Treatment
8.1.1. Dialysis
8.1.1.1. Market Revenue and Forecast
8.1.2. Kidney Transplantation
8.1.2.1. Market Revenue and Forecast
8.1.3. Drug Therapy
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. Renal Failure Treatment Market, by End-use
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast
9.1.2. Specialty Clinics
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment
10.1.2. Market Revenue and Forecast, by End-use
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment
10.1.3.2. Market Revenue and Forecast, by End-use
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment
10.1.4.2. Market Revenue and Forecast, by End-use
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment
10.2.2. Market Revenue and Forecast, by End-use
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment
10.2.3.2. Market Revenue and Forecast, by End-use
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment
10.2.4.2. Market Revenue and Forecast, by End-use
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment
10.2.5.2. Market Revenue and Forecast, by End-use
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment
10.2.6.2. Market Revenue and Forecast, by End-use
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment
10.3.2. Market Revenue and Forecast, by End-use
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment
10.3.3.2. Market Revenue and Forecast, by End-use
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment
10.3.4.2. Market Revenue and Forecast, by End-use
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment
10.3.5.2. Market Revenue and Forecast, by End-use
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment
10.3.6.2. Market Revenue and Forecast, by End-use
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment
10.4.2. Market Revenue and Forecast, by End-use
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment
10.4.3.2. Market Revenue and Forecast, by End-use
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment
10.4.4.2. Market Revenue and Forecast, by End-use
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment
10.4.5.2. Market Revenue and Forecast, by End-use
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment
10.4.6.2. Market Revenue and Forecast, by End-use
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment
10.5.2. Market Revenue and Forecast, by End-use
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment
10.5.3.2. Market Revenue and Forecast, by End-use
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment
10.5.4.2. Market Revenue and Forecast, by End-use
11.1. NIPRO
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Fresenius Medical Care AG
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Baxter
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Medtronic
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. B. Braun SE
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Asahi Kasei Medical Co., Ltd.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. AbbVie Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Nikkiso Co., Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. JMS Co., Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. AstraZeneca
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample